Osteoporosis causes more than two million fractures in the United States every year. Often called the “silent disease,” ...

Osteoporosis weakens bones, increasing fracture risks in the elderly. Maintaining bone health requires exercise, a balanced ...

City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States and a top ...

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...

It’s estimated more than 10 million Americans over the age of 50 live with this "silent disease." Here's what osteoporosis ...

New Innovative Local Treatment for Osteolytic Bone Disease in Multiple Myeloma Jan. 14, 2025 — A team of researchers has developed a new biomaterial with high potential in in the treatment of ...

Merck will partner with Chinese biotech Abbisko Therapeutics to market and sell the bone-tumor treatment pimicotinib globally, expanding its commercialization rights for the drug beyond Asia. The ...

Denosumab-bnht is expected to launch in the US in June 2025 per an agreement with the reference product’s manufacturer, Amgen ...

The study, which is now open, will explore whether denosumab, a human monoclonal antibody that is Food and Drug Administration-approved for the treatment of osteoporosis and bone tumors ...

a human monoclonal antibody that is Food and Drug Administration-approved for the treatment of osteoporosis and bone tumors, can protect and regenerate beta cells, which produce insulin to ...